Your browser is no longer supported. Please, upgrade your browser.
Otonomy, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own0.25% Shs Outstand49.22M Perf Week-15.64%
Market Cap200.93M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float48.11M Perf Month-29.40%
Income-45.00M PEG- EPS next Q-0.22 Inst Own77.20% Short Float2.02% Perf Quarter15.30%
Sales0.30M P/S669.78 EPS this Y11.60% Inst Trans-1.66% Short Ratio2.25 Perf Half Y7.90%
Book/sh1.53 P/B2.86 EPS next Y12.90% ROA-54.60% Target Price- Perf Year34.46%
Cash/sh2.06 P/C2.13 EPS next 5Y20.40% ROE-108.80% 52W Range1.53 - 6.98 Perf YTD-32.46%
Dividend- P/FCF- EPS past 5Y23.30% ROI-81.00% 52W High-37.42% Beta2.08
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low185.62% ATR0.47
Employees49 Current Ratio9.00 Sales Q/Q0.00% Oper. Margin- RSI (14)33.55 Volatility9.51% 8.62%
OptionableYes Debt/Eq0.20 EPS Q/Q32.40% Profit Margin- Rel Volume1.85 Prev Close4.84
ShortableYes LT Debt/Eq0.20 EarningsNov 04 AMC Payout- Avg Volume433.84K Price4.37
Recom1.80 SMA20-22.67% SMA50-15.69% SMA20014.01% Volume803,716 Change-9.71%
Jun-01-20Resumed Oppenheimer Outperform $8
Dec-24-19Initiated Oppenheimer Outperform $8
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Mar-12-18Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Downgrade Piper Jaffray Overweight → Neutral
Aug-30-17Downgrade JP Morgan Overweight → Neutral
Aug-15-17Upgrade JP Morgan Neutral → Overweight
Jun-02-17Initiated Piper Jaffray Overweight $32
May-26-16Initiated WallachBeth Buy $29
Aug-10-15Upgrade Bernstein Mkt Perform → Outperform
May-22-15Downgrade JP Morgan Overweight → Neutral
Jan-05-21 07:30AM  
Dec-17-20 07:00AM  
Dec-15-20 07:50PM  
Dec-14-20 08:59AM  
Nov-30-20 07:30AM  
Nov-16-20 07:30AM  
Nov-06-20 09:03AM  
Nov-04-20 06:55PM  
Oct-28-20 07:30AM  
Oct-02-20 07:30AM  
Sep-15-20 08:52AM  
Sep-10-20 08:41AM  
Sep-02-20 07:30AM  
Aug-17-20 03:30PM  
Aug-04-20 07:25PM  
Aug-03-20 07:30AM  
Jul-28-20 04:05PM  
Jul-15-20 01:15PM  
Jul-13-20 04:01PM  
Jul-09-20 09:00AM  
Jul-08-20 09:01PM  
Jul-07-20 10:44AM  
Jul-06-20 04:04PM  
Jun-30-20 11:42PM  
Jun-17-20 08:31AM  
Jun-15-20 04:05PM  
Jun-11-20 08:41AM  
Jun-10-20 07:30AM  
Jun-08-20 07:30AM  
Jun-01-20 09:56AM  
May-28-20 08:32AM  
May-12-20 08:00AM  
May-07-20 07:30AM  
Apr-09-20 07:30AM  
Mar-26-20 06:47PM  
Mar-09-20 03:53PM  
Feb-27-20 07:25PM  
Feb-24-20 07:30AM  
Feb-21-20 08:37AM  
Feb-20-20 07:30AM  
Jan-28-20 07:30AM  
Jan-23-20 07:30AM  
Jan-09-20 07:30AM  
Jan-07-20 12:31PM  
Jan-02-20 07:28AM  
Dec-24-19 07:24AM  
Dec-16-19 05:45AM  
Dec-03-19 08:51AM  
Nov-26-19 04:05PM  
Nov-22-19 07:11AM  
Nov-05-19 06:55PM  
Oct-29-19 04:05PM  
Oct-28-19 10:32AM  
Oct-01-19 07:30AM  
Sep-26-19 04:05PM  
Sep-17-19 07:30AM  
Aug-27-19 07:10AM  
Aug-01-19 04:20PM  
Jul-25-19 04:05PM  
Jul-11-19 12:33PM  
Jun-12-19 08:00AM  
May-14-19 05:47AM  
May-06-19 06:35PM  
May-02-19 09:00AM  
May-01-19 07:30AM  
Apr-29-19 04:05PM  
Apr-27-19 09:19AM  
Apr-11-19 07:30AM  
Apr-04-19 09:57AM  
Apr-03-19 09:16AM  
Mar-11-19 06:46AM  
Mar-08-19 04:39PM  
Mar-06-19 12:27PM  
Mar-05-19 07:30AM  
Mar-04-19 04:18PM  
Feb-25-19 04:05PM  
Feb-13-19 07:55AM  
Feb-06-19 07:30AM  
Jan-23-19 12:22PM  
Jan-03-19 07:30AM  
Jan-02-19 04:05PM  
Dec-07-18 02:10PM  
Nov-15-18 08:30AM  
Nov-12-18 07:30AM  
Nov-06-18 07:30AM  
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Meniere's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.